MetaCap

Veradermics (MANE) vs Supernus (SUPN)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Supernus is the larger company by market cap ($5.94 billion vs $5.04 billion), about 1.2 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

MANE+216.61%SUPN-41.71%
+333%+134%-65%
Feb 4, 20261 yearNov 20, 2026
MANE+210.60%SUPN-44.61%
+279%+107%-65%
Feb 2, 20265 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

MANE versus SUPN key metrics
MetricMANESUPN
Share price$119.52$28.61
Market cap$5.04B$5.94B
1-day change-3.92%+0.92%
YTD return—-42.43%
1-year return—-36.87%
5-year return—-6.53%
Forward P/E—7.15
EPS (TTM)$-3.89$-0.76
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)—$718.95M
Revenue growth (YoY)—+8.63%
Net income (latest FY)$-70.00M$-38.55M
Gross margin—89.63%
Operating margin—-8.66%
Net margin—-5.36%
52-week high$156.63$42.81
52-week low$32.00$25.92
Distance from 52-week high-23.69%-33.17%
Analyst consensusstrong_buystrong_buy
Avg. price target upside+56.74%+89.23%
Average volume738.22K2.77M
Shares outstanding42.20M207.72M
Employees51827
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

About Veradermics

MANE stock →

Veradermics, Incorporated, a clinical-stage biopharmaceutical company, focused on developing novel therapeutics for dermatologic and aesthetic conditions. The company develops treatments for Pattern Hair Loss affecting adults and children.

Health Care · Biotechnology: Pharmaceutical Preparations · 51 employees

About Supernus

SUPN stock →

Supernus, Inc., together with its subsidiaries, engages in the development, manufacture, and sale of buprenorphine-based prescription drugs for the treatment of opioid dependence and related disorders in the United States, Europe, Canada, Australia, and internationally. It develops medicines to treat substance use disorders.

Health Care · Biotechnology: Pharmaceutical Preparations · 827 employees

MANE vs SUPN FAQ

Which is bigger, Veradermics or Supernus?

Supernus (SUPN) is larger, with a market capitalization of $5.94B compared with $5.04B for Veradermics (MANE).

Are Veradermics and Supernus in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons